US Pharma MarketingModerna still bullish on mRNA, Ipsen's acquisition of Kartos, and more biotech news from The Readout Congress Donald Trump Eli Lilly Newsletters Log In My Account Subscribe Now My Account Settings Complete your personal information for a more tailored experience Billing Log Out A decade of reporting from the frontiers of health and medicine Newsletters Log In My Account Subscribe Now Biotech Pharma Public Health Health Tech Policy Science First Opinion STAT+ STAT Events Search Log In Try STAT+ My Account Home Newsletter The Readout Talawar bets bispecific approach can shake up eczema market Moderna still bullish on mRNA, Ipsen’s…
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Today: We look at the unseemly side of scrutiny of Chinese biotech, have a SPAC for a bispecific maker, and Moderna’s mRNA ambitions enter a new phase despite years of setbacks.
Plus: Clive Meanwell sees AI’s biggest opportunity in the macro processes of biotech drug design, as opposed to the bespoke making of molecules.
Source: STAT News Pharma